Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With AsthmaRecruiting
NCT07525375Phase 2Updated Aug 27, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Czechia, Hungary, Mexico +2 more
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruiting
NCT07681596Phase 1, Phase 2Updated Aug 27, 2026
Sponsor: AstraZeneca
Relapsed or Refractory Multiple Myeloma
United States, Australia
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsRecruiting
NCT07566195Phase 3Updated Aug 27, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease · COPD
France
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruiting
NCT07590934Phase 1, Phase 2Updated Aug 27, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Australia, Germany, Italy, South Korea +2 more
The Eplontersen Pregnancy and Lactation Outcomes StudyRecruiting
NCT07205666N/AUpdated Aug 27, 2026
Sponsor: AstraZeneca
Transthyretin Amyloidosis
Germany
Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.Recruiting
NCT07279935Phase 4Updated Aug 27, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
China
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ AllianceRecruiting
NCT06726720N/AUpdated Aug 27, 2026
Sponsor: AstraZeneca
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
France, Germany
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.Recruiting
NCT07607769N/AUpdated Aug 27, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
Italy
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With AsthmaCompleted
NCT06644924Phase 2Updated Aug 27, 2026
Sponsor: AstraZeneca
Asthma
United States
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompleted
NCT03133546Phase 2Updated Aug 26, 2026
Sponsor: ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer Metastatic
Ireland, Netherlands, Singapore, South Korea, Spain +1 more
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMRecruiting
NCT07690436N/AUpdated Aug 26, 2026
Sponsor: AstraZeneca
Transthyretin Amyloid Cardiomyopathy
United States, Germany, Portugal, Spain, Sweden
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active Not Recruiting
NCT03875235Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
Biliary Tract Neoplasms
United States, Argentina, Bulgaria, Chile, China +12 more
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)Recruiting
NCT06822543Phase 2Updated Aug 26, 2026
Sponsor: Latin American Cooperative Oncology Group
Lung Cancer · Non Small Cell Lung Cancer · Brain Metastases
Brazil
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive Not Recruiting
NCT05367440Phase 1, Phase 2Updated Aug 26, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Australia, Italy, United Kingdom
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive Not Recruiting
NCT04214288Phase 2Updated Aug 26, 2026
Sponsor: AstraZeneca
Advanced ER-Positive HER2-Negative Breast Cancer
United States, Belgium, Canada, France, Georgia +11 more
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruiting
NCT07201558Phase 1Updated Aug 26, 2026
Sponsor: AstraZeneca
Rheumatoid Arthritis · Systemic Lupus Erythematosus
United States, Australia, Belgium, Brazil, China +5 more
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Recruiting
NCT07611110Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Austria, Brazil, Canada +15 more
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruiting
NCT06533826Phase 2Updated Aug 26, 2026
Sponsor: Ana C Garrido-Castro, MD
Breast Cancer · HER2-low Breast Cancer · Metastatic Breast Cancer · HER2-negative Breast Cancer
United States
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active Not Recruiting
NCT04656652Phase 3Updated Aug 26, 2026
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +21 more
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightActive Not Recruiting
NCT06151964Phase 1, Phase 2Updated Aug 26, 2026
Sponsor: AstraZeneca
Overweight and Obesity
Austria, Canada, Germany, Japan, Sweden
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseRecruiting
NCT06283966Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
United States, Argentina, Australia, Austria, Brazil +32 more
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy VolunteersRecruiting
NCT06951880Phase 1Updated Aug 26, 2026
Sponsor: AstraZeneca
Healthy Participants
United States, United Kingdom
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressureRecruiting
NCT06742723Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease and Hypertension
United States, Argentina, Australia, Belgium, Brazil +37 more
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaActive Not Recruiting
NCT06834932Phase 2, Phase 3Updated Aug 26, 2026
Sponsor: AstraZeneca
Dyslipidaemia
China, Hong Kong
Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in BrazilRecruiting
NCT07370194N/AUpdated Aug 26, 2026
Sponsor: AstraZeneca
Hyperkalemia
Brazil

Previous page Next page